Trials / Completed
CompletedNCT03203460
Exercise During Active Surveillance for Prostate Cancer
A Phase II Randomized Controlled Trial of Exercise in Prostate Cancer Patients Undergoing Active Surveillance
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- University of Alberta · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The broad goal of the Exercise During Active Surveillance for Prostate Cancer (ERASE) trial is to examine the effects of exercise in prostate cancer patients undergoing active surveillance.
Detailed description
The ERASE Trial will be a phase II randomized controlled trial. A total of 66 men with low- or intermediate-grade clinically localized prostate cancer undergoing active surveillance will be randomized to either a 12-week of supervised high-intensity aerobic interval training or usual care. The primary outcome will be peak oxygen consumption (VO2peak) as a measure of physical fitness. The secondary outcomes include tumour-related biomarkers, fear of cancer progression, quality of life, and psychological distress. Exploratory outcomes will include indicators of cancer progression including prostate-specific antigen. Based on this sample size, our study has 80% power with a two-tailed alpha \<0.05 to detect a clinically meaningful effect of 3.5 ml/kg/min on our primary outcome of VO2max. This power will also be sufficient for detecting differences in our secondary biomarkers and patient-reported outcomes if the effects are at least moderate (i.e., a standardized effect size of d=0.60).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | High-intensity aerobic interval training (HIIT) | A 12-week, supervised, HIIT aerobic exercise program consisting of alternating vigorous- and low-intensity intervals |
Timeline
- Start date
- 2018-07-01
- Primary completion
- 2020-05-31
- Completion
- 2021-05-31
- First posted
- 2017-06-29
- Last updated
- 2022-04-18
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT03203460. Inclusion in this directory is not an endorsement.